Novo Nordisk Faces a Pivotal August as Legal, Commercial, and Competitive Pressures Converge

Novo Nordisk enters a pivotal summer with Q2 earnings, a court fight over Zepbound ads, and a discounted Ozempic launch in South Africa amid rising generic competition.

The Danish drugmaker enters a defining stretch of the summer with two major events that could reshape investor sentiment. On August 5, Novo Nordisk will report second-quarter earnings, and just twelve days later, a US court will hear its request for a preliminary injunction against Eli Lilly over advertising claims for Zepbound. Between those dates, a stock that has clawed back some ground must prove its recovery has staying power.

Shares closed at €44.65 on Tuesday, up 2.13 percent on the day and 6.07 percent higher over the past week. Yet the equity remains 18.61 percent below its 52-week peak of €54.86, a reminder of how much ground was lost during a difficult stretch for the GLP-1 leader.

A Legal Gambit in New Jersey

Novo Nordisk filed suit against Eli Lilly in New Jersey on July 21, alleging that the US rival’s advertising for Zepbound contains misleading claims about the drug’s efficacy. The company will seek a preliminary injunction on August 17 to halt the contested campaigns. Lilly has rejected the accusations and pledged a vigorous defense.

The legal action comes at a moment when Novo Nordisk is trying to close the gap with Lilly on the regulatory front. On July 15, the European Commission approved both the oral Wegovy pill and a new high-dose 7.2-mg injection pen. Both products are intended to recapture market share that Zepbound has steadily eroded.

Whether the higher dose and the oral formulation can reverse the trend will be a dominant theme in the months ahead. Novo Nordisk has pegged weight loss with the 7.2-mg dose at up to 19 percent. The critical question is whether that clinical edge translates into rapid prescription growth.

A Discounted Ozempic Copy in South Africa

Beyond the courtroom, Novo Nordisk is taking a different approach to defending its franchise. Together with healthcare company Acino, it has launched Extensior in South Africa, an authorized, lower-cost version of Ozempic that uses the same active ingredient, semaglutide, at roughly 15 percent below the original’s price.

The timing is strategic. The local patent on semaglutide expired in March, and India’s Sun Pharmaceutical Industries had already secured the first approval for a generic version. A dozen more applications are pending with South Africa’s medicines regulator, signaling that the price war over semaglutide is only beginning.

The market welcomed the news. Shares added 2.37 percent to €44.76 on the day of the announcement, extending a weekly gain of about three percent. Still, the stock remains well below its 2025 summer high.

Analyst sentiment is split. The average rating is “Buy,” but price targets have been cut roughly 14 percent over the past three months — a sign that competitive pressure is filtering into Wall Street models. The upcoming earnings report will offer the first real test of how generic competition is affecting revenue.

The Bull Case: Pill Momentum and Technical Signals

For optimists, the technical picture has brightened. The stock trades 9.96 percent above its 50-day moving average of €40.60 and also sits above its 200-day line of €40.36 — a configuration that suggests sentiment has shifted after a weak prior year.

The oral Wegovy version is gaining traction, accounting for about 34 percent of roughly 495,500 weekly prescriptions. The FDA confirmed earlier in 2025 that semaglutide production now meets US demand nationwide, removing supply constraints as a headwind.

If the August 5 earnings report shows the pill is attracting new patients without cannibalizing injectable sales, the stock could make a run toward its 52-week high of €54.86.

The Bear Case: Lilly’s Dominance and Valuation Concerns

The counterargument rests on Lilly’s continued market power. Zepbound held a 58.9 percent share of the US GLP-1 market at the end of July. Over a 12-month horizon, Novo Nordisk stock is still down 4.91 percent despite the recent recovery.

Chart watchers also see reason for caution. The relative strength index stands at 63.2, approaching overbought territory. Novo Nordisk shares have historically tended to break lower after earnings when the outlook fails to meet elevated expectations.

A failed injunction bid on August 17 could send the stock back toward its 50-day moving average. The same risk applies if second-quarter margins suffer under the weight of the pill rollout.

What the August Catalysts Mean

As long as demand for the Wegovy pill continues to grow and the 7.2-mg dose gains traction in the US and EU, the trend remains cautiously positive. August 5 will be the first test: any adjustment to the 2026 annual guidance is likely to set the direction. If management sounds confident about the CagriSema pipeline for 2027, the stock could challenge resistance near €50.

A negative outcome in court on August 17 would likely lead to stabilization rather than a sharp sell-off. The same holds true if Lilly’s own oral GLP-1 candidates begin to look more threatening. In that scenario, the stock would remain within the trading range of the past 30 days.

With annualized volatility at 27.24 percent and a market capitalization of €189.68 billion, investors should brace for meaningful swings in both directions this month. The next few weeks will determine whether Novo Nordisk’s legal and commercial counteroffensive is enough to regain the initiative — or whether Lilly’s momentum is simply too strong to reverse.